[
  {
    "title": "Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients",
    "url": "https://ejhp.bmj.com/content/27/e1/e41",
    "authors": "Luis Margusino-Framiñán, Purificación Cid-Silva, Sandra Rotea-Salvo, Álvaro Mena-de-Cea, Francisco Suárez-López, Pilar Vázquez-Rodríguez, Manuel Delgado-Blanco, Ana Isabel Sanclaudio-Luhia, Isabel Martín-Herranz, Ángeles Castro-Iglesias",
    "institution": "Pharmacy Service, Universitary Hospital of A Coruña, A Coruña, Spain. Division of Clinical Virology, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), Sergas, University of A Coruña (UDC), A Coruña, Spain. Infectious Diseases Unit. Internal Medicine Service, Universitary Hospital of A Coruña (CHUAC), A Coruña, Spain. Hepatology Unit, Digestive System Service, University Hospital of A Coruña (CHUAC), A Coruña, Spain. Information Systems Department, University Hospital of A Coruña, A Coruña, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2019-002060",
    "filters": {
      "actSubs": ["Sofosbuvir / Velpatasvir", "Ribavirin", "Glecaprevir / Pibrentasvir"],
      "indication": ["Hepatitis C Genotype 3", "Liver Fibrosis"],
      "statedClass": [],
      "studyDesign": ["Cohort (Prospective Observational Study)"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["51 - 100"],
      "numPrescriptions": [],
      "criteriaMethod": ["Fisher’s Exact Test", "Mann-Whitney U Test", "Real-Time Polymerase Chain Reaction"],
      "studyLength": ["1 year - 2 years"],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": ["safetyProfile"],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": []
    }
  },
  {
    "title": "Evaluation of the stability of vancomycin solutions at concentrations used in clinical services",
    "url": "https://ejhp.bmj.com/content/27/e1/e87",
    "authors": "Morgane Masse, Stéphanie Genay, Anthony Martin Mena, Natacha Carta, Damien Lannoy, Christine Barthélémy, Bertrand Décaudin, Pascal Odou",
    "institution": "Univ. Lille, CHU Lille, ULR 7365–GRITA–Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2019-002076",
    "filters": {
      "actSubs": ["Vancomycin hydrochloride"],
      "indication": [],
      "statedClass": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Laboratory"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["HPLC-DAD", "Mann-Whitney U Test"],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": []
    }
  },
  {
    "title": "Long-term stability of ready-to-use norepinephrine solution at 0.2 and 0.5 mg/mL",
    "url": "https://ejhp.bmj.com/content/27/e1/e93",
    "authors": "Sixtine Gilliot, Morgane Masse, Stéphanie Genay, Damien Lannoy, Christine Barthélémy, Bertrand Décaudin, Pascal Odou",
    "institution": "EA 7365–GRITA–Groupe de Recherche sur les formes Injectables et les Technologies Associées, University of Lille, CHU Lille, F-59000 Lille, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2019-002146",
    "filters": {
      "actSubs": ["Norepinephrine"],
      "indication": [],
      "statedClass": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Laboratory"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Fast Reversed-Phase HPLC", "Cochran Test"],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": []
    }
  },
  {
    "title": "National reporting system for drug shortages: classification and trends in reported causes from 2015 to 2018",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A5.2",
    "authors": "A Benhabib, P Maison",
    "institution": "French National Agency for Medicines and Health Products Safety, Health Products Survey, Saint-Denis, France. Strasbourg Faculty of Pharmacy, Hospital Pharmacy, Strasbourg, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.12",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": ["2 years - 5 years"],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": []
    }
  },
  {
    "title": "Cost efficacy analysis of abiraterone in newly diagnosed high risk metastatic castration sensitive prostate cancer",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A4.1",
    "authors": "A Soares, A Alcobia",
    "institution": "Hospital Garcia De Orta, Pharmacy Department, Almada, Portugal",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.8",
    "filters": {
      "actSubs": ["Abiraterone"],
      "indication": ["Prostate Cancer (Metastatic Castration Sensitive)"],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Portugal"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": ["clinicalTrials"],
      "youngPharma": [],
      "nextStep": []
    }
  },
  {
    "title": "Application of a time slot model in oncology: delivery planning and process optimisation",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A8.2",
    "authors": "C Bertino, M Di Gerardo, A Pirrone, E Dalla Fontana, G Caravella, A Spagnuolo, R Cursano",
    "institution": "Università Degli Studi Di Milano, Scienze Farmaceutiche-Scuola Di Specializzazione Farmacia Ospedaliera, Milano, Italy. Asst Melegnano Martesana, Farmacia, Vizzolo Predabissi, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.18",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": ["pharmacoeconomy"],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": ["stock"],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": ["institutional"],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": []
    }
  },
  {
    "title": "Envisioning sustainability in personalised medicine: Fondo AIFA 5% and the Italian example",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A7.2",
    "authors": "F Bocchio, M Tizzoni, M Calvi, A Di Benedetto",
    "institution": "Fondazione Irccs Policlinico San Matteo Pavia, Uoc Farmacia, Pavia, Italy. Universita’ Degli Studi Di Milano, Scuola Di Specializzazione in Farmacia Ospedaliera, Pavia, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.16",
    "filters": {
      "actSubs": ["Venetoclax", "Eltrombopag", "Pembrolizumab", "Ruxolitinib", "Blinatumomab", "Trabectedina", "Cenegermin"],
      "indication": ["Leukaemia (Acute Myeloid)", "Lymphoma (Mantle Cell)", "Pure Red Cell Aplasia", "Lymphoma (Hodgkin)", "Lymphoma (non-Hodgkin)", "Myeloproliferative Neoplasm (BCR/JAK2-Rearranged)", "Leukaemia (Acute Lymphoblastic)", "Graft Versus Host Disease", "Ovarian Carcinoma", "Ovarian Serous Adenocarcinoma", "Neurotrophic Keratitis"],
      "statedClass": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": ["10 - 50"],
      "criteriaMethod": [],
      "studyLength": ["1 year - 2 years"],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": ["personalized"],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": ["selection"],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": ["multidisciplinary"],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": []
    }
  },
  {
    "title": "Smartphone applications for patients diagnosed with genitourinary tumours: analysis of the quality using the mobile application rating scale",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A6.1",
    "authors": "MÁ Amor, R Collado-Borrell, V Escudero-Vilaplana, A Ribed-Sánchez, A Melgarejo-Ortuño, FJ García-Moreno, S García-Sánchez, Á Narrillos-Moraza, P Ruiz-Briones, A Herranz-Alonso, M Sanjurjo-Sáez",
    "institution": "Servicio De Farmacia, Hospital General Universitario Gregorio Marañón, Madrid, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.13",
    "filters": {
      "actSubs": [],
      "indication": ["Genitourinary Cancers", "Prostate Cancer", "Cervical Cancer", "Testicular Cancer", "Ovarian Carcinoma"],
      "statedClass": [],
      "studyDesign": ["Cross-Sectional Study"],
      "setting": [],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["MARS (Multivariate Adaptive Regression Splines)"],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": ["mobileVR"],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": []
    }
  },
  {
    "title": "Biological drugs for the treatment of moderate and severe plaque psoriasis: a cost analysis and an application of a correlation analysis to investigate cost effectiveness",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A1.2",
    "authors": "N Sagaria, D Mengato, I Corbucci, G Felluga, G Morandell, A Tavella",
    "institution": "School of Hospital Pharmacy, Department of Pharmaceutical Sciences University of Padova, Padova, Italy. Bolzano General Hospital, Hospital Pharmacy Department, Bolzano, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.2",
    "filters": {
      "actSubs": ["Adalimumab", "Infliximab", "Guselkumab"],
      "indication": ["Psoriasis (Moderate to Severe Plaque)"],
      "statedClass": ["Biosimilars"],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Psoriasis Area and Severity Index (PASI)", "Correlation Analysis"],
      "studyLength": ["3 months - 5 months"],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"]
    }
  },
  {
    "title": "Economic comparison of therapeutic alternatives for firstline treatment of multiple myeloma",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A2.2",
    "authors": "MD Gil-Sierra, S Fenix-Caballero, MDP Briceño-Casado, M Dominguez-Cantero, EJ Alegre-Del Rey",
    "institution": "Hospital Universitario De Puerto Real, Pharmacy, Puerto Real, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.4",
    "filters": {
      "actSubs": ["Daratumumab", "Lenalidomide", "Bortezomib", "Thalidomide", "Melphalan", "Prednisone", "Dexamethasone"],
      "indication": ["Multiple Myeloma (Newly Diagnosed)"],
      "statedClass": [],
      "studyDesign": ["Systematic Review"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "questPatient": [],
      "questProfessional": [],
      "selection": [],
      "stock": [],
      "autoDispensing": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": ["clinicalTrials"],
      "youngPharma": [],
      "nextStep": []
    }
  }
]